Sunday, July 3, 2022
No Result
View All Result
Medical Finance
  • Home
  • News
  • Interviews
  • Mediknowledge
  • Insights From Industry
  • Thought Leaders
  • Coronavirus
  • Whitepapers
  • Home
  • News
  • Interviews
  • Mediknowledge
  • Insights From Industry
  • Thought Leaders
  • Coronavirus
  • Whitepapers
No Result
View All Result
Medical Finance
No Result
View All Result
Home Coronavirus

Monoclonal antibodies found to prevent lung inflammation in SARS-CoV-2-Omicron-infected mice

by Medical Finance
in Coronavirus
Study: Resilience of S309 and AZD7442 monoclonal antibody treatments against infection by SARS-CoV-2 Omicron lineage strains. Image Credit: nnattalli/Shutterstock
9
SHARES
104
VIEWS
Share on FacebookShare on Twitter

In a recent study posted to the bioRxiv* pre-print server, researchers investigated how monoclonal antibodies (MAbs), S309 and AZD7442, reduced lung infection in mice infected with the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variant of concern (VOC) Omicron’s BA.1, BA.1.1, and BA.2 sublineages.

Study: Resilience of S309 and AZD7442 monoclonal antibody treatments against infection by SARS-CoV-2 Omicron lineage strains. Image Credit: nnattalli/Shutterstock
Study: Resilience of S309 and AZD7442 monoclonal antibody treatments against infection by SARS-CoV-2 Omicron lineage strains. Image Credit: nnattalli/Shutterstock

S309, the parent of Sotrovimab, is a cross-reactive SARS-CoV MAb, whereas the AZD7442, clinically known as Evusheld, is a combination of AZD8895 and AZD1061 MAbs. While the S309 binds to a conserved epitope on the receptor-binding domain (RBD) of SARS-CoV-2 spike (S) glycoprotein, the Evusheld binds to non-overlapping receptor-binding motif (RBM) epitopes. Although previous studies reported that several MAbs lose their neutralizing potency against Omicron sublineages in vitro, their effects in vivo are unknown.

About the study

In the current study, researchers assessed the in vitro neutralizing activity of S309, AZD8895, AZD1061, and AZD7442 MAbs against BA.1, BA.1.1, and BA.2 sublineages in Vero-transmembrane serine protease 2 (TMPRSS2) cells. To this end, they used mAbs with fragment crystallizable (Fc) modifications, S309-LS, AZD8895-YTE/TM, AZD1061-YTE/TM, and AZD7442-YTE/TM, that extend antibody half-life in humans and reduce Fc effector functions.

For the in vivo studies, they used S309-LS and AZD7442 MAbs, with only the TM mutations (not the YTE mutations). The research team intraperitoneally injected a 200 μg mAb dose in human keratin 18 (K18)-human angiotensin-converting enzyme 2 (hACE2) transgenic mice infected with BA.1, BA.1.1, or BA.2 sublineages, and harvested sera samples six days post-infection (dpi) for BA.2, and seven dpi for BA.1.1 and BA.1. Notably, all these sublineages replicate rapidly in the lungs of K18-hACE2 mice.

Findings

Compared to the ancestral D614G SARS-CoV-2 strain, incubation of S309-LS, AZD7442-YTE/TM, and AZD8895-YTE/TM, AZD1061-YTE/TM antibodies with BA.1 sublineage reduced their in vitro neutralization potency by 2.5-fold, 25-fold, 118-fold, and 206-fold, respectively.

Although S309-LS and AZD8895-YTE/TM were slightly less effective against BA.1.1 than BA.1 in vitro, the authors observed a 1700-fold reduction in the neutralizing potency of AZD1061-YTE/TM. Yet, the AZD7442-YTE/TM combination showed some inhibitory activity against the BA.1.1 variant.

Overall, S309 retained in vitro neutralizing potency against BA.1 and BA.1.1 sublineages but had reduced in vitro neutralizing activity against BA.2, whereas AZD7442 combination showed reduced yet some neutralizing activity against all three Omicron lineages.

In BA.1 and BA.1.1-infected mice, S309-LS mAb reduced viral burden in the lung and nasal turbinates at seven dpi compared to control group mice treated with isotype mAb. The control group K18-hACE2 mice had increased expression of several cytokines and chemokines, including granulocyte-macrophage colony-stimulating factor (GM-CSF), interferon-gamma (IFN-γ), interleukin-1-beta (IL-1β), and interleukin 6 (IL-6). However, BA.1 or BA.2-infected mice (but not BA.1.1) treated with AZD7442-TM mAb had reduced pro-inflammatory cytokine and chemokine expression.

Despite their low in vitro neutralization potency against all Omicron sublineages, S309-LS and AZD7442-TM efficiently reduced viral burden and cytokine levels in the lungs of the infected mice. S309-LS treatment resulted in a 742-fold reduction in viral ribonucleic acid (RNA) in the lungs of BA.2-infected mice; however, it could not reduce the viral burden in the nasal turbinates of these mice.

AZD7442-TM treatment reduced viral burden in the lungs by 91-fold, four-fold, and >100,000-fold in BA.1, BA.1.1, and BA.2-infected mice, respectively. Similar to S309-LS, its protective effect remained limited on the viral burden in the nasal washes of infected mice, similar to how their parent MAbs COV2-2196 and COV2-2130 showed less protection in nasal washes against several SARS-CoV-2 VOCs.

Several studies in non-human primates have shown that the concentrations of MAbs in nasal washes are approximately 0.1% of those found in the serum, thus rationalizing the diminished effect of these MAbs in these tissues.

For the AZD7442-TM, with Fc modifications, antibody-mediated reductions in lung viral titers directly correlated with its neutralization activity against the Omicron sublineages. For S309-LS, changes in the neutralization potency did not linearly correlate to changes in viral titers. Nevertheless, it conferred adequate protection in the lungs of BA.2-infected mice despite a substantial loss in the neutralizing activity in vitro.

Conclusions

The study built upon recent in vitro findings of BA.1 sublineages and showed the level of protection conferred against all three circulating Omicron sublineages by treatment with two MAbs, S309 and AZD7442-TM.

The findings showed that while S309-LS and AZD7442-TM retained inhibitory activity against these Omicron sublineages, their altered in vitro neutralization potency did not directly impact their in vivo potency and dosing in the clinical setting.

The study also highlighted that for these MAbs, Fc effector functions compensated for the loss in the neutralization potency against SARS-CoV-2 variants and worked as a protective mechanism in vivo.

Thus, despite losses in neutralizing potency in cell culture, S309-LS or AZD7442-TM prevented inflammation in the lungs of mice infected with Omicron variants.

Overall, the study experiments remarkably demonstrated how Fc effector functions could contribute to the resilience of some mAbs against Omicron and other VOCs.

*Important notice

bioRxiv publishes preliminary scientific reports that are not peer-reviewed and, therefore, should not be regarded as conclusive, guide clinical practice/health-related behavior, or treated as established information.

Total
0
Shares
Share 0
Tweet 0
Pin it 0
Share 0
Medical Finance

Medical Finance

Related Posts

Study: BNT162b2 Protection against the Omicron Variant in Children and Adolescents. Image Credit: Dkoi / Shutterstock

How well does the BNT162b2 vaccine protect children and teens against Omicron?

by Medical Finance
July 3, 2022
0

A recent study published in the New England Journal of Medicine investigated the vaccine efficiency of the Pfizer BioNTech (BNT162b2)...

mRNA-1273 and BNT162b2 COVID-19 vaccines induce slightly different immune responses

mRNA-1273 and BNT162b2 COVID-19 vaccines induce slightly different immune responses

by Medical Finance
July 3, 2022
0

In a recent study published in the journal Science, researchers observed differential effector functions of antibodies elicited by Pfizer’s BNT162b2...

Study: Effect of Early Treatment with Ivermectin among Patients with Covid-19. Image Credit: NIAID

COVID-19 study proves ivermectin ineffective

by Medical Finance
July 3, 2022
0

A recent study published in the New England Journal of Medicine investigated the impact of ivermectin, an antiparasitic drug, as...

Study: RNA editing increases the nucleotide diversity of SARS-CoV-2 in human host cells. Image Creditr: Orpheus FX / Shutterstock

Evidence SARS-CoV-2 undergoes ADAR-mediated A-to-I RNA editing in human cells

by Medical Finance
July 3, 2022
0

In a recent study published in the journal PLOS Genetics, researchers explored severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) ribonucleic acid...

Study: Bats host the most virulent—but not the most dangerous—zoonotic viruses. Image Credit: shutter_o / Shutterstock.com

Bats carry some of the most virulent, but not the most dangerous zoonotic viruses

by Medical Finance
July 3, 2022
0

The current coronavirus disease 2019 (COVID-19) pandemic caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is considered a...

Study: Exome-wide association study to identify rare variants influencing COVID-19 outcomes: Results from the Host Genetics Initiative. Image Credit: angellodeco / Shutterstock.com

TLR7 and MARK1 genomic variants impact COVID-19 prognosis

by Medical Finance
July 3, 2022
0

As of April 3, 2022, coronavirus disease 2019 (COVID-19) has caused almost 6.2 million deaths worldwide. While in many developed...

Next Post
Study: Human Galectin-9 Potently Enhances SARS-CoV-2 Replication and Inflammation In Airway Epithelial Cells. Image Credit: Corona Borealis Studio / Shutterstock.com

Researchers investigate Galectin-9 as a new treatment target for COVID-19

Study: Risk of Myocarditis and Pericarditis Following BNT162b2 and mRNA-1273 COVID-19 Vaccination. Image Credit: Teeradej / Shutterstock.com

Study evaluates risk estimates of myocarditis and pericarditis from mRNA-1273 and BNT162b2 vaccines

0 0 votes
Article Rating
Subscribe
Login
Notify of
guest
guest
0 Comments
Inline Feedbacks
View all comments

Support

  • Contact
  • Disclaimer
  • Home
  • Privacy Policy
  • Terms And Conditions

Categories

  • Coronavirus
  • Insights From Industry
  • Interviews
  • Mediknowledge
  • News
  • Thought Leaders
  • Whitepapers

More News

  • Study: A Feasible Alternative Strategy Targeting Furin Disrupts SARS-CoV-2 Infection Cycle. Image Credit: CROCOTHERY/Shutterstock
    An alternative strategy targeting furin disrupts SARS-CoV-2 infection cycle
  • HIV 620x480
    Researchers discover a new function of anti-HIV-1 antibodies
  • Home
  • Privacy Policy
  • Contact
  • Disclaimer
  • Terms And Conditions

© 2022 Medical Finance - Latest Financial and Business News

No Result
View All Result
  • Interviews
  • Mediknowledge
  • News
  • Insights From Industry
  • Coronavirus
  • Thought Leaders
  • Whitepapers
wpDiscuz
0
0
Would love your thoughts, please comment.x
()
x
| Reply